Please login to the form below

Not currently logged in
Email:
Password:

drug safety

This page shows the latest drug safety news and features for those working in and with pharma, biotech and healthcare.

Biogen loses another pipeline drug to toxicity concerns

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug. Just a few days after calling time on its Eisai-partnered Alzheimer’s drug  elenbecestat, Biogen has another pipeline casualty – this time its ... The decision – announced in an  update

Latest news

More from news
Approximately 3 fully matching, plus 400 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Patient safety drive. For John Haanen, demands for safer immunotherapies are also a factor in the FDA’s call for biomarker and assay harmonisation. ... The potential downside, Magid Diefenbach said, is that immunotherapy firms may focus drug

  • Real-world studies Real-world studies

    myriad of information, from safety monitoring and drug utilisation studies of marketed products in the EU to routine safety monitoring of marketed products and filling evidentiary gaps for particular rare diseases ... trial recruitment, support

  • Streamlining clinical trials – why better data use is key Streamlining clinical trials – why better data use is key

    Compliance requirements are in place to ensure patient safety when a drug ultimately comes to market. ... endpoints and patient safety, which can lead to better data, faster enrolment and reduced patient burdens.”.

  • Five questions guiding the way to actual patient-centricity Five questions guiding the way to actual patient-centricity

    We also learned that patients’ trust, encouraged by a better comprehension of our work, has been correlated with better clinical outcomes and features, including drug adherence and reporting of safety concerns. ... 3 Are we ready to offer value (beyond

  • Behaviour change – a missing ingredient? Behaviour change – a missing ingredient?

    It already invests hugely in long-term development programmes to understand drug efficacy and safety; the step required to take the same long-term view on implementing behaviour change programmes is ... If behavioural aspects are investigated and

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics